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Due to substantial improvement in diagnosis and treatment of oral cavity cancer, a better understanding of
the patient care needs to be revised. We reviewed literature related to OCC and discussed current general
management approaches and related long-term radiation toxicities to emphasize the multidisciplinary team
involvement. New technical modalities and patient quality of life parameters should be an integral and paramount
state in the clinical evaluation to significantly contribute to reduce secondary side effects.
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Oral cavity cancer (OCC) accounts for approximately
28% of all head and neck malignancies. In 2014 there
will be estimated 11.920 new patients diagnosed in
United States and 2.070 deaths [1]. It is associated with
tobacco smoking and alcohol abuse. Most cases occur in
males, at a rate of 2:1 relative to female, although this
trend is dropping, linked to the increase of tobacco use
in women [2]. Over the past 20 years, there has been an
increment in the incidence of oral cavity cancer in
younger non-smokers and non-drinkers. Recent studies
emphasize, in these emerging cancer patient popula-
tions, the role of Human Papilloma Virus (HPV) infection,
especially types 16 – known as a high oncogenic causative
agent in cervical cancer [3,4].
The oral cavity consists of various anatomic sites:
upper and lower lips, gingiva-buccal sulcus, buccal
mucosa, upper and lower gingiva, alveolar ridge, hard
palate, floor of mouth and anterior 2/3 of the mobile
tongue. These areas have a rich lymphatic drainage and
primary regional node dissemination is to levels I to III
[5]. Diagnosis and management are established by
clinical examination and imaging evaluation – CT and/or* Correspondence: fradefelice@hotmail.it
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unless otherwise stated.MRI from base of skull to clavicle should be routine to
assess the loco-regional extent of the primary tumor; CT
ad/or PET should be performed to estimate the presence
of distant metastasis [6]. Tumors are conventionally
staged according to the American Joint Committee on
Cancer classification system (Table 1) [7]. Squamous cell
carcinomas represent approximately 90% of OCC; al-
though uncommon, various subtypes are described, such
as basaloid squamous cell carcinoma, sarcomatoid car-
cinoma and verrucous squamous cell carcinoma. These
histological variants are correlated with differences in
prognosis – good prognosis for verrucous carcinoma,
only. The remaining 10% is predominantly adenoido-
cystic carcinoma [6]. Stage of disease at diagnosis predicts
survival rates. The most significant prognostic factor is
cervical lymph-nodes status. Patients without lymph-node
metastasis had a 5-year cancer specific survival of 94%
compared to 51% in patients with clinically positive cer-
vical lymph nodes [8]. HPV-related tumors may assure
better prognosis; otherwise definitive conclusion in sur-
vival benefit should not be drawn [9].
Due to substantial improvement in diagnosis and
treatment of oral cavity cancer, understanding of the
patient care needs to be revised. We reviewed literature
related to OCC and discussed current general manage-
ment approaches and related long-term radiation toxi-
cities to emphasize the need for multidisciplinary teamal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 TNM staging system for oral cavity
Primary tumor (T)
T1 Tumor ≤2 cm in greatest dimension
T2 Tumor >2 cm and ≤4 cm in greatest
dimension
T3 Tumor >4 cm in greatest dimension
T4a Moderately advanced local disease.
Tumor invades adjacent structures only
(through cortical bone [mandible or
maxilla], into deep [extrinsic] muscle of
tongue, maxillary sinus, skin of face)
T4b Very advanced local disease. Tumor
invades masticator space, pterygoid
plates, or skull base and/or encases
internal carotid artery
Regional Lymph Nodes (N)
N1 Metastasis in a single ipsilateral lymph-
node, ≤3 cm in greatest dimension
N2a Metastasis in a single ipsilateral lymph-
node, >3 cm and ≤6 cm in greatest
dimension
N2b Metastasis in multiple ipsilateral lymph-
nodes, none >6 cm in greatest
dimension
N2c Metastasis in bilateral or controlateral
lymph-nodes, none >6 cm in greatest
dimension




Table 2 Constraint of head and neck organs at risk
OAR Theorical constraint
Spinal cord D max <45 Gy (0.5 cc =48 Gy)
TMJ
Homolateral D5% ≤70 Gy
Controlateral D5% ≤70 Gy
Mandible < 65 Gy
Tooth < 60 Gy
Parotid gland
Homolateral -
Controlateral D mean ≤26 Gy; D50% ≤30 Gy
Submandibular gland
Homolateral -
Controlateral D mean ≤26 Gy; D50% ≤30 Gy
OAR = organ at risk; TMJ = temporomandibular joint; D = dose.
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for patient’s quality life should be integral and para-
mount in the clinical evaluation to significantly contri-
bute to reduce secondary side effects.
Review
General management
Surgery, radiation therapy (RT), chemotherapy or com-
binations of these therapeutic modalities represent the
classical options for managing OCC. The appropriate
strategy is based on stage of disease. The current stan-
dard recommendation is surgical resection. The choice
of a combined modality approach is indicated in ad-
vanced disease. Adjuvant radiation therapy is required
for stages > T2, ≥ pN2b, positive or close surgical mar-
gin, extracapsular nodal spread, and perineural invasion.
Adjuvant chemoradiation may be beneficial in high-risk
patients, defined as extranodal extension and/or positive
surgical margins [10]. Primary definitive radiotherapy is
performed in patients with medical contraindication to
surgery or in surgical approaches related to significant
functional loss [11]. Considering that physiologic func-
tions may be affected, a multidisciplinary team (surgeon,radiotherapist, oncologist, maxillo-facial prosthodontists,
pathologist, and radiologist) evaluation should be the
standard.
Overview
In treating OCC, the goals are provided for best func-
tional results and minimal risk of serious complications.
Treatment advances are partly responsible for improve-
ment in survival. Therefore a bigger number of survivors
run into long-term consequences of cancer treatment.
Nowadays managing and preventing sequelae after sur-
gery, radiation therapy with or without chemotherapy,
are paramount [12]. Treatment complications depend
on specific site and stage of primary tumor, as well as
treatment technique.
The extent of surgical procedure depends on the
degree of tissue involvement. Tumor should be resected
with transoral, transcervical or via mandibulectomy
approach, and elective (cN0) or therapeutic (cN+) neck
dissection is performed [11]. Peri- and post- treatment
complications include bleeding, infection, fistulas, aspi-
ration and swallowing or speech deficits.
Regarding RT, the risk of radiation-induced toxicities
is significant in OCC, considering the anatomic proxi-
mity to various structures. The ionizing radiation pro-
duces damage in normal tissues located in the treatment
field. Improvement in modern RT techniques, such as
intensity modulated RT (IMRT), has minimized the se-
verity of late toxicities by reducing dose to organs at risk
(OARs). The maximum dose limits of standard fractio-
nation for OARs are listed in Table 2. However, clinical
trials are limited by size and there is no clear evidence
to support interventions to improve the loss of func-
tional aspects in OCC patients treated with radiation
therapy [13]. Thus we will focus on this aspect.
Table 3 Salivary glands
Localisation Gland Type
Lips Upper lip Serous
Lower lip Serous
Cheek Buccal mucosa Mixed
(predominantly mucous)
Parotid Serous
Hard palate Postero-lateral hard palate Mucous
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and dental evaluation
The severity of radiation therapy-related toxicities im-
poses an adequate assessment, support and surveillance
before, during and after treatment. Multidisciplinary eva-
luation, according to a uniform policy, is an integral
component of patient care. Patient should be educated
about preventive strategies. Collaborative efforts between
clinicians and patients could potentially sustain changes
in habits’ conduct.
Patients should be incited to change their “unnecessary”
habits, because smoke and alcohol consumption may
reduce the efficacy of treatment and increase the risk of
new OCC following the first primary cancer [14]. This
etiological background is an important factor in field can-
cerization [15]. Due to prolonged carcinogen exposure,
patients are susceptible for developing a second primary
tumor, with a risk 2.8 times greater than expected [16].
Programs that support quitting or limiting consumption
of tobacco and alcohol could be beneficial.
Adequate nutritional support is extremely important
in OCC patients, to attenuate weight loss. Losing >10%
of body weight during therapy is correlated with in-
creased complications and deterioration in global quality
of life [17]. Patient should be well-informed about the
importance of maintenance of good nutrition. Modifica-
tion of the consistency of food may be inevitable. Dietary
management and supplement drinks could be useful to
maintain caloric need; tube placement should be recom-
mended in patients with severe pre-treatment weight loss.
Several trials have demonstrated the advantage of prophy-
lactic gastrostomy tube placement to minimize weight
loss, in patients submitted to chemoradiotherapy [18].
Before starting radiotherapy a careful and complete
dental and oral evaluation is recommended. Extraction of
teeth in poor condition should be carried out, to re-
duce the subsequent risk of oral cavity damage. Due to
radiation-induced xerostomia and salivary gland dysfunc-
tion, patients are at risk of dental complications, such as
caries, dento-alveolar infection, bone demineralization
and osteoradionecrosis. An excellent oral hygiene is im-
portant and patient should be advised to practice it. Soft
toothbrush is available for patient to facilitate daily oral
hygiene procedures. Topical fluoride applications should
be started and continued after treatment to optimize









Italic type indicate major salivary glands.Sequelae of treatment: focus on xerostomia, trismus,
radiation caries and osteoradionecrosis
The late toxicities of radiation therapy protocols – with
or without concomitant chemotherapy – included xeros-
tomia, trismus, fibrosis and muscle atrophy, caries, and
osteoradionecrosis.Xerostomia represents the most common side effect of
radiation therapy. It is defined as objective – unstimulated
saliva flow rate <0.1 ml/min – and subjective – more than
45% reduction in unstimulated saliva flow rate – sensation
of dry mouth [19]. Salivary glands have an high impact
on quality of life. Saliva plays a central role in dental
and oral care, in lubricating mucosa, in contributing to
antimicrobial activity. Saliva daily volume is produced
by submandibular glands (about 70%; serous and
mucous secretion), parotid gland (about 20%; serous
secretion) and minor salivary glands (less than 10%;
mucous secretion, except Von Ebner serous glands)
[20]. The submandibular and the minor salivary glands
guarantee oral moinsture; parotid glands provide watery
saliva during eating [21]. Details of salivary glands’
characteristic are shown in Table 3 [20].
Damage to major and minor salivary glands causes al-
teration in quantity, quality and consistency of saliva.
Salivary glands are radio-sensitive organs. Hyposalivation
depends on reduced water and protein rich secretion in
parotid glands and loss of function depends on mucous
secretion of submandibular glands and minor salivary
glands. Saliva turns into a white and viscous fluid,
secondary to pH acidification, decrease in bicarbonate
concentration and increase in sodium, calcium and mag-
nesium. In addition to pH and electrolyte levels modifi-
cations, immunoproteins concentration is also altered,
resulting in deleterious effects on oral flora with increase
in Streptococcus mutans, Candida species and Lactoba-
cillus species [22].
Although irradiation-induced damage in salivary gland
was first described in 1911, its mechanism is still a de-
bate [23]. Radiation-effect on salivary glands has been
tested principally in parotid glands. Regional differences in
radio-sensitivity have been, described in rat parotid gland,
considered as plausible model for human circumstances
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sitivity to radiation exposure than the caudal part. The
mechanism of damage is related to the radiation effects
on muscarinic receptor induced secretary responsiveness,
with consequent destruction of serous cells and loss of
serous properties in saliva [25]. This is a possible expla-
nation for the high radio-sensitivity of the parotid glands
compared with the relative radio-resistence of the other
major salivary glands, which contain much higher level of
mucous cells [26]. According to radiobiological principles,
metal ions are the agents responsible for irradiation
damage, inducing lipid peroxidation. Therefore the radio-
sensitivity of salivary glands is linked to their content of
secretory granules [27]. The time kinetics of damage is
expressed in two phases: at first (0–60 days) salivary gland
dysfunction depends on plasma membrane damage, later
(60–240 days) on “traditional” killing of progenitor cells
[28]. Salivary gland hypofunction and consequent xerosto-
mia can persist and develop more than 5 years after ra-
diation treatment, significantly increasing the risk of oral
and dental disease and aggravating the difficulties with
speaking and eating [29].
Last decades are characterized by improvement in radi-
ation therapy technology and this guarantees higher rates
of salivary glands sparing. IMRT, compared with conven-
tional 3-D radiotherapy, significantly reduces the inci-
dence of xerostomia (at 12 months: 38% vs 74%; at
24 months: 29% vs 83%) and results in better recovery of
saliva secretions [30]. However these results are not
completely satisfactory, because the analysis had exclu-
sively included oropharynx and hypopharynx cancers and
therefore salivary glands are not always included in the
target volume. But instead in OCC, due to primary tumor
localization, it is necessary to deliver a high dose of radi-
ation to the oral cavity. Consequently, it is much more
complicated to protect salivary glands, because of their
anatomical location, size and bilateral symmetry, and often
glands are in (or close to) the target.
Parotid sparing RT is recommended method for the pre-
vention of xerostomia. The protective effect of Amifostine
and Pilocarpine is not so definite. Amifostine administra-
tion reduced acute (from 78% to 51%, p-value <0.0001) and
chronic (from 57% to 34%; p-value 0.002) xerostomia, but
it is also combined with nausea, vomiting and hypotension
[31]. Administration of oral Pilocarpine during radiation
therapy did not improve xerostomia, whereas its efficacy
could be dependent on mean dose to parotid gland [32].
Artificial saliva could ameliorate hyposalivation, but its
effect is transient and, considering the cost, most pa-
tients prefer the frequent use of water. Stem cell replace-
ment could be a potential valid therapy for xerostomia;
further researches are necessary [33].
Trismus is a debilitating condition, defined as reduced
jaw mobility, limited to a maximum inter-incisor openingmeasurements of 35 mm or less. Historically the word
trismus was used to indicate a difficulty in opening the
mouth, secondary to tetanus spasm of the masticator
muscles [34]; nowadays it refers to all conditions of li-
mited mouth opening, such as direct trauma, oral infec-
tion, oral surgical procedures, drug history and head and
neck tumors [35].
Trismus may be induced by radiation therapy and it is a
well known late complication of treatment. According to
the Common Terminology Criteria for Adverse Events
(CTCAE) v3.0 the degree of trismus is evaluated assessing
masticatory dysfunction. It is graded as G1 (decreases
range of motion without impaired eating), G2 (decreases
range of motion requiring small bites, soft foods or pu-
rees) and G3 (decreases range of motion with inability to
adequately aliment or hydrate orally). The loss of jaw mo-
bility is generally the result of radiation-induced fibrosis of
temporomandibular joint and/or masticatory muscles. Fi-
brosis process can be divided in three histopathological
phases: an initial pre-fibrotic non-specific inflammatory
phase, with loss of natural endothelial barrier and direct
exposure of connective tissue; a constitutive organized
phase, characterized by high density of fibrotic cellular ele-
ments; and a late fibroatrophic phase, with tissue densifi-
cation and remodeling [36]. Trismus is a rapid process
during the first 9 months after radiotherapy, and then its
progress becomes slower over later months [37]. Trismus
occurs with variable incidence and severity, ranging from
5% to 42%, if temporomandibular joint and/or masticatory
muscles are included in the target volume [38,39]. High
radiation dosage >55 Gy to these structures are related to
significantly high incidence of trismus, with an increased
risk of 24% with every additional 10 Gy [38,40]. Pterygoid
muscles irradiation is responsible for reduction in lateral
and protrusive jaw movements. High radiation dose to
these muscles correlates to increase in mandibular
dysfunction. Goldstein et al. [41] investigated the effects of
radiation therapy on jaw opening and they found that
irradiation of pterygoid muscles was sufficient to in-
duce trismus in 31% of patients. Recently, different trials
showed a better trismus profile in patients receiving IMRT
than those receiving 3-D RT, sparing pterygoid muscles,
especially lateral pterygoid ones [38,42-44].
The consequences of trismus can be serious; it can
cause difficulty in eating, swallowing and maintaining
adequate oral hygiene. Appropriate post-radiation tris-
mus therapy is still unknown. Encouraging patient to
maintain muscles mobilization is paramount. Specific
active and passive exercise, using a TheraBite device or
tongue blades, may improve organ’s function, minimi-
zing the effects of radiation [37,45]. Botulinum toxin,
injected transcutaneously into the masseter muscle, did
not improve trismus [46]. If conservative treatments fail,
coronoidectomy should be considered [47].
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plex oral cavity complication. Indirect effects are more
important than direct radiogenic damage to the denti-
tion [48]. Dentition integrity is influenced by tooth-level
radiation dose, reduced salivary flow rate, topical fluo-
ride use, oral hygiene status and time after the end of
radiation therapy [49]. Induced caries showed same mor-
phological patterns of decay with natural caries: acce-
lerated demineralization and reduced remineralisation of
tooth structure, changes in translucency, reactionary dentin
and intralobular dentin deposition [48]. Cariogenesis is
predominantly associated with hyposalivation and its
related consequences, particularly altered composition of
saliva and shift in oral microflora to a highly cariogenic
bacteria flora [50]. Radiation-related caries are, therefore,
indirect complications of dentition, with a rapid onset and
progression [51]. Clinically radiation caries are not related
to severe pain. Alteration starts mainly on the labial sur-
face (the tooth surface adjacent to the lips); due to low pH
saliva and loss of remineralisation capacity, the minerals
of enamel and dentin are easily dissolved; then carious le-
sion progresses to affect the entire crown and results in
increased friability and breakdown of tooth [52]. Instead,
direct effects of radiation on tooth structures are still not
well-known. Several studies in vitro have demonstrated
changes in enamel and dentin proprieties at tooth dose
greater than 60 Gy [49,53,54]. Although further investiga-
tions are necessary to evaluate the real impact of radiation
dose on dentition, if possible, in daily practice, a tooth
dose <60 Gy should be respected.
Clinical management of radiation-related caries is
essentially based on clinical experience and preventive
oral health care programs should be paramount. From a
dental point of view, maintenance of meticulous oral hy-
giene, daily use of topical fluoride and control of cario-
genic microflora play a central role in radiation caries
prevention.
Osteoradionecrosis (ORN) is a well documented late
complication of radiation therapy for OCC. It is a slow
process, not apt to heal spontaneously, characterized by
chronic, painful necrosis associated with late sequestration
and permanent bone deformity [55]. Biologically, ORN is
characterized by hypoxic, hypocellular and hypovascular
tissue, followed by tissue breakdown [56]. Hypoxia and
hypocellularity are secondary to radiation-induced activa-
tion and dysregulation of fibroblastic activity that caused
vascular fibrosis and thrombosis [57]. Because of its rela-
tively poor vascularization, the mandible, especially the
buccal cortex of premolar, molar and retromolar regions,
is much more vulnerable than other bones of the head
and neck district. Mandible is exclusively supplied by the
inferior alveolar artery (IAA), a branch of the maxillary
artery; therefore the obliteration of the IAA causes an
ischemic necrosis in irradiated atrophic tissue [58,59].Since the first ORN description in 1922, several scales
have been proposed to provide a universal scoring system
to classify ORN [60-64]. There is, however, a general con-
sensus about the CTCAE v3.0 as grading system for the
late effects of radiation. It grades ORN considering clinical
presentation, radiographic evidence and medical treat-
ment. ORN is defined as G1 (asymptomatic, radiographic
findings only), G2 (symptomatic and interfering with
function, but not interfering with activities of daily living;
minimal bone removal indicated, such as minor seques-
trectomy), G3 (symptomatic and interfering with activities
of daily living; operative intervention or hyperbaric oxygen
indicated) or G4 (disabling).
Radiation and its characteristics (total dose, fraction-
ation, type of energy, field size) are the principal related
factors of ORN. After radiotherapy, patients are at greater
risk of ORN. Conditions that predispose are: high radia-
tion dose to mandible >65 Gy, hyperfractionation radia-
tion therapy scheme, volume of the mandible included in
the target, and maximal dose coverage close to the bone,
such as implant source. Early presentation – less than
2 years after radiation therapy – is correlated to a high
radiation dose, whereas late stage – several years after
radiation therapy – is associated to trauma within the
compromised tissue. The incidence of ORN reported in
literature varies from 35% to 0.9%, as a result of diffe-
rences in the observation periods. The range is most com-
monly from 11.8% to 3% in recent reports, because of
technical progress in radiation techniques [65]. IMRT pro-
vides a better target volume dose coverage, sparing OARs
and therefore minimizing toxicities [66]. Tooth extraction
and implant surgery represent promoting factors in the
development of ORN. Traditional thinking about pre-
irradiation healthy dental extractions do not appear to re-
duce the risk of ORN; the only teeth that really need to be
extracted before radiation therapy are those in poor condi-
tion that will reside in the high dose radiation field [67].
Although Starcke et al. [68] indicated that a shorter time
period is not associated with increased ORN risk, an inter-
val period of at least 14 days between extractions and
radiation therapy is recommended to allow complete hea-
ling of the extraction site. Implant placement well corre-
lates with ORN risk. To reduce the probability of ORN
onset, implant surgery should be performed minimum
14 days before radiotherapy or from 6 to 24 month after
treatment [69].
The better treatment of ORN is prevention; dental
care and oral hygiene represents the key. When ORN
occurs, treatment ranges from conservative methods to
segmental mandibular resection with free vascularised
bone grafting, for advanced stage. However elective sur-
gical procedure must be considered very carefully after
irradiation. Based on radiation-induced fibroatrophic
damage, new therapeutic regimens have been tested.
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fibrotic agents, increasing bone formation and mucosal
healing [70]. The real efficacy of hyperbaric oxygen
therapy remains remarkable debate. The rationale is its
potential role in stimulating monocyte and fibroblast
function and neoangiogenesis. But final results are not
satisfactory, thus treatment with hyperbaric oxygen
should not be recommended [71].
Conclusion
OCC remains a great challenge of the head and neck
oncological scenario, in achieving local tumor control and
overall survival benefit within tolerable long-term toxicity.
The main purpose of this article was to provide a rationale
and stronger knowledge of issues and to propose methods
of prevention of radiation morbidity. Treatment improve-
ment and patient care should advance together.
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